The effects of L-arginine mono(2-mercaptoethanesulfonate) on the ischemic and reperfused heart

A. Cargnoni, L. Comini, A. Boraso, F. De Giuli, C. Scotti, R. Ferrari

Research output: Contribution to journalArticlepeer-review


We evaluated the effectiveness of L-arginine mono(2-mercaptoethanesulfonate) (argimesna) to limit the extent of myocardial damage resulting from 60 minutes of severe ischemia followed by 30 minutes of reperfusion in the Langendorff-perfused rabbit heart. Argimesna is a sulfhydryl group containing molecule which has no effect on glutathione status or on the total thiol pool. The effects of 10 -6 M argimesna were compared with those of 10 -6 M L-arginine and of 10 -6 M sodium salt of 2-mercaptoethanesulfonate (mesna). Pretreatment of the hearts with 10 -6 M argimesna resulted in marked myocardial protection, measured in terms of improved recovery of developed pressure (p <0.01), reduced release of creatine kinase (p <0.01), maintenance of mitochondrial function and increased stores of ATP on reperfusion. On reperfusion less oxidative stress developed, as indicated by less accumulation of oxidized glutathione (p <0.01). These effects were specific for argimesna; no significant protection could be found for mesna and L-arginine. The beneficial effects of argimesna could not be explained by hemodynamic differences or effects on anaerobic metabolism. Neither is it likely that argimesna acts as a free radical scavenger at the concentrations employed. The protection may be achieved by maintenance of -SH groups during ischemia and reperfusion.

Original languageEnglish
Pages (from-to)179-187
Number of pages9
Issue number3
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The effects of L-arginine mono(2-mercaptoethanesulfonate) on the ischemic and reperfused heart'. Together they form a unique fingerprint.

Cite this